Tag: Preсlinical Studies

Russian TB vaccine has successfully completed preclinical studies

Minister of Health of the Russian Federation Veronika Skvortsova made an announcement on the Margins of UN General Assembly.

Stealth BioTherapeutics develops new drug in collaboration with Evotec

Stealth BioTherapeutics announced that it is advancing a new pipeline candidate into investigational new drug (IND) enabling studies in collaboration with long-term partner Evotec AG.

Researchers developed a new class of drugs to reduce cardiovascular risk

Researchers from Cleveland Clinic have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

FPI conducts preclinical trials of drug intended to save seriously injured

Human trials of the drug being developed to save the seriously injured and to extend the "golden hour" - the time regarded as the most critical for saving lives - can begin at least in three years

Pre-clinical studies of the Russian-Vietnamese drug started

Scientists of the Komi Scientific Center have begun pre-clinical studies of the drug improving performance and resistance to stress originating from the tropical plants extracts.

Alpha Genesis Primate Research Center to expand its European capabilities

The Alpha Genesis Primate Research Center, the Research Division of Alpha Genesis Incorporated, is to take on additional European business commitments as the firm continues its expansion efforts on the continent.

Cleara Biotech advances in the development of new therapeutics

Cleara Biotech B.V., a Netherlands-based biopharmaceutical company, announced the creation of three public-private partnerships to discover and develop new therapeutics.

OBL Pharm meets GMP requirements of the Russian Federation

In early June 2018, the Russian Ministry of Industry and Trade issued to OBL Pharm the Conclusion GMP-0144-000263/18 on compliance with the requirements of the good manufacturing practice (GMP of the Russian Federation).

Epigen Biosciences licenses kidney disease medicine to Novo Nordisk

Epigen Biosciences entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease.

Leading Russian institutions became a part of BioTox international cluster

The cluster was established in order to combine the competencies of its participants to perform non-clinical studies on medical and environmental safety in accordance with the principles of Good Laboratory Practice.

Preclinical studies from Advaxis show the anti-cancer potential

Advaxis, a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential.

Janssen Biotech will buy BeneVir Biopharm

Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will acquire BeneVir Biopharm, a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.

Researchers from Koltsovo developed a drug for treatment of depression

The researchers from Koltsovo have developed a new drug for such patients. It will allow not only to treat depression, but also cope with severe neurological diseases.

Kineta starts drug development collaboration with Genentech

Kineta announced that it has entered into an exclusive option and license agreement with Genentech to develop Kineta's α9/α10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain.

Chinese biotech Biocytogen received $65 million investment

CMB International Capital Corporation, a wholly-owned subsidiary of China Merchants Bank, provided a $65 million budgeting for Beijing Biocytogen, a gene targeted animal model and service supplier.

Frontage Laboratories acquired Concord Biosciences

Frontage Laboratories, Inc., a global contract research organisation (CRO), announced the acquisition of Concord Biosciences (Cleveland, USA) formerly known as Ricerca Biosciences, LLC, a preclinical CRO.